Search
I4MDS consortium: advancing MDS treatment and understanding
The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.
Read moreGrants & abstract awards
EHA Travel GrantsThe call for travel grant applications will be open from January 1, 2025 until March 1, 2025 (23:59 CET). New: Grant applications have been integrated into the EHA2025 Abstract Submission form.
Read moreFrom bedside to Brussels: hematology at the forefront of EU health policy
Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.
Read moreAbstract & Clinical Case Submission
Abstract submission is an important part of the 7th European CAR T-cell Meeting.
Read moreRegistration & accommodation
Register here
Individual RegistrationRegistration fee includes:
Access to the scientific and educational sessions of the meeting. Digital meeting materials including the program and abstract book. Networking opportunities during breaks, receptions and dinners.
Dates and deadlines
You may find in this page all the dates and deadlines related to the EHA2025 Congress. All deadlines, except if mentioned differently, end at 23:59 CET/CEST.
The timelines will be updated regularly.
General Information
June 5, 2025
EHA2025 Congress platform opens
June 12-15, 2025
EHA2025 Milan, Italy - In-person and live stream
Location
Allianz MiCo, Milano Convention Centre
August 15, 2025
EHA2025 Congress platform closes
Scientific Program Committee (SPC) Chair
Prof.
Travel Grants
Travel grant application is now closed. Travel grants are intended to support young investigators to participate in the 7th European CAR T-cell Meeting; therefore, applicants should be 40 years of age or younger.
Read more7th European CAR T-cell Meeting
The European Hematology Association (EHA) and the EBMT are excited to announce the 7th edition of the jointly organized European CAR T-cell Meeting.
Read moreSelected EMA news
December 2024New information on approved medicines
Sarclisa (isatuximab) - new indication
Treatment of multiple myeloma (a type of blood cancer)
Withdrawal of applications for extension of indication
Inaqovi (cedazuridine / decitabine)
Treatment of different types of blood cancer
Direct Healthcare Professional Communication (DHPC)
Pegasys (peginterferon alfa-2a)
Treatment of…